Christopher Su

907 total citations
30 papers, 297 citations indexed

About

Christopher Su is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Christopher Su has authored 30 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Economics and Econometrics. Recurrent topics in Christopher Su's work include Economic and Financial Impacts of Cancer (9 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Christopher Su is often cited by papers focused on Economic and Financial Impacts of Cancer (9 papers), Health Systems, Economic Evaluations, Quality of Life (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Christopher Su collaborates with scholars based in United States, South Africa and Italy. Christopher Su's co-authors include Ryan D. McMahan, Rebecca L. Sudore, Ajjai Alva, Brie Williams, Rashmi Sharma, Yousef Zakharia, Vivek Narayan, Bradley A. McGregor, Xīn Gào and Toni K. Choueiri and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American Geriatrics Society.

In The Last Decade

Christopher Su

26 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Su United States 11 149 114 45 44 44 30 297
Elaine Yu United States 10 191 1.3× 102 0.9× 24 0.5× 27 0.6× 39 0.9× 34 314
Stuthi Perimbeti United States 8 108 0.7× 42 0.4× 32 0.7× 34 0.8× 41 0.9× 45 253
Madison Grogan United States 10 190 1.3× 65 0.6× 23 0.5× 33 0.8× 19 0.4× 30 268
Martine Bomb United Kingdom 6 226 1.5× 65 0.6× 26 0.6× 33 0.8× 55 1.3× 11 380
Melissa S. Dillmon United States 7 270 1.8× 74 0.6× 50 1.1× 30 0.7× 30 0.7× 10 360
Joshua J. McFarlane United States 7 109 0.7× 96 0.8× 23 0.5× 43 1.0× 26 0.6× 8 240
Scott Berry Canada 11 208 1.4× 103 0.9× 113 2.5× 31 0.7× 28 0.6× 14 345
Irina Ghislain Belgium 6 230 1.5× 94 0.8× 29 0.6× 25 0.6× 35 0.8× 7 327
Luz Stella García Colombia 11 172 1.2× 97 0.9× 130 2.9× 22 0.5× 29 0.7× 26 416
Ana I. Velázquez United States 9 173 1.2× 55 0.5× 14 0.3× 25 0.6× 41 0.9× 50 332

Countries citing papers authored by Christopher Su

Since Specialization
Citations

This map shows the geographic impact of Christopher Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Su more than expected).

Fields of papers citing papers by Christopher Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Su. The network helps show where Christopher Su may publish in the future.

Co-authorship network of co-authors of Christopher Su

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Su. A scholar is included among the top collaborators of Christopher Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Su. Christopher Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Su, Christopher, Wael Saber, Aasthaa Bansal, et al.. (2025). Out-of-Pocket Expenditures and Financial Hardship Among Patients With Myelodysplastic Syndrome Undergoing Allogeneic Transplant or Hypomethylating Agent / Supportive Care (BMT CTN 1102). Transplantation and Cellular Therapy. 31(7). 459.e1–459.e6. 1 indexed citations
2.
Collins, Jennifer, Jill Randall, Christopher Su, et al.. (2025). Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT. Transplantation and Cellular Therapy. 31(12). 959–972.
3.
Su, Christopher, Scott D. Ramsey, & Veena Shankaran. (2025). Can We Use Credit Data to Assess Cancer Financial Hardship?. JAMA Oncology. 11(12). 1420–1420.
4.
Banerjee, Rahul, Andrew J. Cowan, Paul A. Carpenter, et al.. (2024). Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24(7). 446–454.e3. 16 indexed citations
5.
Deng, Lei, Christopher Su, Xingxing Zang, et al.. (2023). Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways. Cancers. 15(13). 3372–3372. 11 indexed citations
6.
Su, Christopher & Veena Shankaran. (2023). Digital symptom assessment tools: the next frontier in financial toxicity screening. Nature Reviews Clinical Oncology. 21(2). 85–86. 1 indexed citations
7.
8.
Su, Christopher & Veena Shankaran. (2022). Defining the Role of the Modern Oncology Provider in Mitigating Financial Toxicity. Journal of the American College of Radiology. 20(1). 51–56. 3 indexed citations
9.
Curran, Catherine, Elio Adib, Petros Grivas, et al.. (2021). Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. Clinical Genitourinary Cancer. 20(1). 11–16. 5 indexed citations
10.
Patel, Minal, Reshma Jagsi, Ken Resnicow, et al.. (2021). A Scoping Review of Behavioral Interventions Addressing Medical Financial Hardship. Population Health Management. 24(6). 710–721. 17 indexed citations
11.
Vincent, T., Christopher Su, Jeremy M. G. Taylor, et al.. (2021). Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Urologic Oncology Seminars and Original Investigations. 39(7). 437.e1–437.e9. 10 indexed citations
12.
Adra, Nabil, Alexandra Sokolova, Adam Kessel, et al.. (2021). Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(6_suppl). 100–100. 7 indexed citations
13.
Koshkin, Vadim S., Yilun Sun, Dory Freeman, et al.. (2021). Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.. Journal of Clinical Oncology. 39(6_suppl). 443–443. 4 indexed citations
14.
Su, Christopher, et al.. (2021). Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. Journal of Hematology & Oncology. 14(1). 115–115. 23 indexed citations
15.
Koshkin, Vadim S., Yi Sun, Christopher Su, et al.. (2020). 771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer. Annals of Oncology. 31. S594–S594. 2 indexed citations
16.
Ravi, Praful, Charlene Mantia, Christopher Su, et al.. (2020). Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.. Journal of Clinical Oncology. 38(15_suppl). 5077–5077. 1 indexed citations
17.
Cheng, Haiying, H. Dean Hosgood, Lei Deng, et al.. (2019). Survival Disparities in Black Patients With EGFR-mutated Non–small-cell Lung Cancer. Clinical Lung Cancer. 21(2). 177–185. 15 indexed citations
18.
Su, Christopher, Amit Bhargava, Chirag Shah, et al.. (2018). Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community. Clinical Lung Cancer. 19(5). e767–e773. 11 indexed citations
19.
Su, Christopher, Vincent Chau, Balázs Halmos, et al.. (2018). The impact of primary care access on mortality in lung cancer patients from Bronx, New York.. Journal of Clinical Oncology. 36(15_suppl). e18614–e18614. 1 indexed citations
20.
Shum, Elaine, Christopher Su, Rasim Gucalp, et al.. (2017). P1.07-027 PD-L1 Expression Analysis in African American (AA) and Hispanic Lung Cancer Patients at a Minority-Based Academic Cancer Center. Journal of Thoracic Oncology. 12(11). S2006–S2006. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elaine Yu Breakdown of academic impact, for papers by Stuthi Perimbeti Breakdown of academic impact, for papers by Madison Grogan Breakdown of academic impact, for papers by Martine Bomb Breakdown of academic impact, for papers by Melissa S. Dillmon Breakdown of academic impact, for papers by Joshua J. McFarlane Breakdown of academic impact, for papers by Scott Berry Breakdown of academic impact, for papers by Irina Ghislain Breakdown of academic impact, for papers by Luz Stella García Breakdown of academic impact, for papers by Ana I. Velázquez
Rankless by CCL
2026